TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenThe p53 pathway in breast cancerCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesRedox Control of Multidrug Resistance and Its Possible Modulation by AntioxidantsBiomarkers in triple negative breast cancer: A reviewResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerNVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent mannerCA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancerPrognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerFrequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancersMutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.Chemosensitivity and p53; new tricks by an old dogAltered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalLate onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.Race and the prognostic influence of p53 in women with breast cancer.Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Cell death signaling and anticancer therapyProtein-Protein Interaction Network could reveal the relationship between the breast and colon cancerPrognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayTargeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancerAnti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 statusp53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients.Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyRecent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.Clinical outcomes based on multigene profiling in metastatic breast cancer patients
P2860
Q21092375-CE5DB2D4-DC4D-440F-8DC3-BD9C6BC1C646Q24802349-6D903328-1727-4602-B664-DFF8B66FF0BAQ26743510-B74043D6-D89A-452F-9728-FC4541451984Q26765805-3DBEDD35-048C-47A7-8164-376661998737Q26775094-AA9E23CA-0EB6-478B-8E03-64C04C3CDD13Q27006998-59EF2E85-BF7C-47AB-9257-02F7D96F48A5Q28473504-964BE558-C4B5-49D0-9B76-3BEA33BA82C4Q28483767-0C00D24D-E07C-4CFD-B675-A3C92B07B327Q33256427-90265AB0-77EA-42CC-B707-A3CC99E6884BQ33304691-00343AF6-88F6-4DC3-9A65-AC69A3DEB52BQ33379276-3A5230A5-DF32-4564-8904-E02B9F577AA6Q33618285-02B4528A-D70C-49FB-AB06-37AB5751408AQ33739325-74453F9B-664A-482A-9303-36522E235024Q33865095-F9C35183-D6D5-4A64-956F-2D2C325E9056Q33893910-BA935CE2-ED7A-452C-A2A0-EA9638A81EA3Q33939753-3C087989-FC35-4E25-A8AC-C7E63F9205C3Q34294432-C4ABA564-BE95-4D31-8B22-76E2349EFE2CQ34328227-BCE63D76-663F-43EC-A3E2-B63AB4355E16Q34576275-DAC21892-9B5E-4A91-90A6-C4EDA828E8BEQ34654543-17DF5F7A-CF7A-427C-BA3A-62FF91ADA8E7Q34796332-DC2DD078-7E81-4DF5-B94C-FACE94032836Q34825969-0B2F2154-56D8-4F40-861E-836F80EA8FA5Q34908845-6A7ED3C2-0DE9-4669-9C84-F7AB93B8F77DQ35029530-C5322EF9-39AB-4CC0-938F-D87947809302Q35146274-24A75C34-3F87-4867-944D-E030FD9E1701Q35161695-D1473A74-C0D5-4F39-8F9C-2A054A889D7BQ35237197-61EB04F7-C4BF-4938-8CE6-2F8C9E9C264EQ35605783-17A21031-A014-4D61-A9A8-F3E3A98595E4Q35779325-15CC6824-4D0E-46CB-8B72-116C8CB6CF78Q35972102-3656C446-6EFB-4782-B0EB-B1E05F35BE08Q36006139-8892C38E-27E4-41E0-ADE3-4F3161120A60Q36245341-B3C94E5D-243B-43DD-86BC-82C6A63980CDQ36385696-52444C8A-9485-4956-89F9-468221887C63Q36544248-D76B14E2-775B-468B-A4B0-F61D915826A1Q36599308-89BB839E-EB0C-4E6A-A850-DE592238C6FDQ36623220-84B48A64-3D75-4CF4-9BFE-FFB5C6937D47Q36644176-E4C9C203-211B-49FD-B4CF-1948B1ABFA94Q36667443-1DC6A442-5D3E-4A50-A6B0-E6FA8BB31558Q37208757-A7B200CB-0620-4379-959A-EC598FD5CEE4Q37718221-3F2E08D4-6A01-4656-BF0C-6B78F705BF75
P2860
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@ast
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@en
type
label
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@ast
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@en
prefLabel
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@ast
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@en
P2093
P1476
TP53 mutation and p53 overexpr ...... ent in breast cancer patients.
@en
P2093
Janschek E
Kandioler-Eckersberger D
Mittlböck M
Schlagbauer-Wadl H
P407
P577
2000-01-01T00:00:00Z